Reported revenues increased by 25.3% year-on-year (YoY, compared to H1 2014) to reach US$ 393.8m in H1 2015. *Pro forma Group revenues for the same period increased by 37.1% to reach US$ 431.0m
EBITDA reached US$ 68.9m (+32.6% YoY), resulting in a Group EBITDA margin of 17.5%. Pro forma Group EBITDA was US$ 79.2m (+52.5% YoY, margin: 18.4%)
Adjusted EPS reported at US$ 0.25, Pro forma US$ 0.27 and basic EPS reported at US$ 0.21
Strong performance across all major assets, contribution from acquisitions and better than expected impact from Dubai mandatory insurance
Revenue per patient increased to US$ 125.7 (+10.4% YoY) with pro forma equivalent reaching US$ 129.6 (+13.8% YoY). The sharp growth in revenue per patient reflects the implementation of the new capabilities focussed strategy
Patient visits grew by 28.7% YoY to reach 1.48m. Pro forma patient visits amounted to 1.73m (+50.4% YoY)
Number of doctors employed reached 803 (+48% YoY)
Healthcare segment of Distribution division increased sales by 19%
